Compare AU

Compare CURE vs. BCOM

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Global X Bloomberg Commodity Complex ETF (BCOM). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

BCOM

Popularity

Low

Low

Pearlers invested

82

2

Median incremental investment

$619.50

$3,193.50

Median investment frequency

Monthly

Fortnightly

Median total investment

$1,323.41

$6,199.54

Average age group

> 35

> 35


Key Summary

CURE

BCOM

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

BCOM.AX was created on 2023-07-05 by Global X. The fund's investment portfolio concentrates primarily on broad market commodities. The investment objective of the Fund is to provide investors with a return, that tracks the performance of the Bloomberg Commodity Index Excess Return 3 Month Forward, plus earn interest returns through exposure to cash and/or money market instruments (before fees and expenses).

Top 3 holdings

Natera Inc (3.41 %)

Incyte Corp (2.94 %)

Gilead Sciences Inc (2.88 %)

GLOBAL X 1-3 Month T-Bill ETF USD Acc (83.90 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.45 %

0.6 %


Key Summary

CURE

BCOM

Issuer

Global X

Global X

Tracking index

S&P Biotechnology Select Industry

Bloomberg Commodity Index Excess Return 3 Month Forward - AUD - Benchmark TR Net

Asset class

ETF

ETF

Management fee

0.45 %

0.6 %

Price

$49.94

$10.81

Size

$38.065 million

$40.659 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

0.51 %

Market

ASX

ASX

First listed date

12/11/2018

04/07/2023

Purchase fee

$6.50

$6.50


Community Stats

CURE

BCOM

Popularity

Low

Low

Pearlers invested

82

2

Median incremental investment

$619.50

$3,193.50

Median investment frequency

Monthly

Fortnightly

Median total investment

$1,323.41

$6,199.54

Average age group

> 35

> 35


Pros and Cons

CURE

BCOM

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

  • Higher price growth

Cons

  • Lower price growth

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

CURE

BCOM

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home